search
Back to results

Phenotypic Properties in Individuals Affected With XLHED (ECP-014)

Primary Purpose

X Linked Hypohidrotic Ectodermal Dysplasia

Status
Completed
Phase
Locations
United States
Study Type
Observational
Intervention
Sponsored by
Edimer Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an observational trial for X Linked Hypohidrotic Ectodermal Dysplasia focused on measuring XLHED, HED, Hypohidrotic Ectodermal Dysplasia, X Linked Hypohidrotic Ectodermal Dysplasia

Eligibility Criteria

4 Years - undefined (Child, Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Females of original gender of age 18-45 years who are registered and attending the 2013 NFED Family Conference. This will include those at risk for XLHED and controls
  2. XLHED-affected males of original gender of age 4 yrs and up who are registered and attending the 2013 NFED Family Conference
  3. Provide informed consent/assent

Exclusion Criteria:

  1. Subjects who are not able or are not willing to comply with the procedures of this protocol
  2. Subjects with any major medical problem that will prevent them from participating in this study
  3. Male subjects who participated in the prior study ECP-003 sponsored by Edimer Pharmaceuticals Inc. in May 2011 in San Francisco, CA
  4. Males at risk for XLHED with prior genetic testing that did not reveal an EDA mutation

Sites / Locations

  • Omni Houston Hotel

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Arm Label

XLHED affected Males

Females affected by XLHED

Unaffected females

Arm Description

All males ages 4 and up affected by XLHED

Adult females (ages 18-45) affected by XLHED

Unaffected adult female controls (ages 18-45)

Outcomes

Primary Outcome Measures

To collect demographic and clinical status information in XLHED-affected males, adult females at risk for XLHED and adult female controls
To collect demographic and clinical status information in XLHED-affected males, adult females at risk for XLHED and adult female controls using a medical questionnaire
To test and refine a computer algorithm for facial recognition of XLHED
To test and refine a computer algorithm for facial recognition of XLHED based on 2D facial photographs obtained from subjects at risk for XLHED and controls
To evaluate 3-dimensional facial imaging technology for mapping craniofacial development in XLHED males
To evaluate 3-dimensional facial imaging technology for mapping craniofacial development in XLHED males
To test for the presence of genetic mutations in subjects at risk for XLHED
To test for the presence of genetic mutations in subjects at risk for XLHED who lack prior genetic diagnosis
To test the validity of a using saliva samples for genetic testing
To test the validity of a using saliva samples for genetic testing buy simultaneously perform genetic testing on blood and salvia and comparing the mutations identified

Secondary Outcome Measures

Full Information

First Posted
June 3, 2013
Last Updated
November 25, 2013
Sponsor
Edimer Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT01871714
Brief Title
Phenotypic Properties in Individuals Affected With XLHED
Acronym
ECP-014
Official Title
Phenotypic Properties in Individuals Affected With X-linked Hypohidrotic Ectodermal Dysplasia: Symptoms and Facial Recognition
Study Type
Observational

2. Study Status

Record Verification Date
November 2013
Overall Recruitment Status
Completed
Study Start Date
May 2013 (undefined)
Primary Completion Date
July 2013 (Actual)
Study Completion Date
September 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Edimer Pharmaceuticals

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The current study design incorporates two previously developed, non-invasive approaches to characterize the phenotype of individuals affected with XLHED.
Detailed Description
The current study design incorporates two previously developed, non-invasive approaches to characterize the phenotype of individuals affected with XLHED. Facial 3-dimensional (3D) imaging will be created from white-field morphometric scanning (Hammond, 2004. The 3D facial photographs collected from males (ages 4 years and up) will be used to develop a non-invasive screening tool, which could enable detection of craniofacial signs of XLHED in the newborn period. 3D facial profiling has been reported to be effective in identifying HED (Dellavia et al., 2008), but the technology does not yet meet the ease-of-use criteria for a universal screening tool. Standard 2-dimensional (2D) frontal and lateral facial photographs will be taken of the same XLHED-affected male subjects as well as of adult females (ages 18-45 yrs) at risk for being XLHED carriers and unaffected adult female controls. The 2D facial photographs will serve a dual purpose; the first being to beta-test a previously developed algorithm to identify males affected with XLHED (Automatic Phenotype Identification of XLHED Patients Final Report, December 25, 2012, unpublished), and the second to adapt the facial recognition algorithm to identify female carriers of XLHED.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
X Linked Hypohidrotic Ectodermal Dysplasia
Keywords
XLHED, HED, Hypohidrotic Ectodermal Dysplasia, X Linked Hypohidrotic Ectodermal Dysplasia

7. Study Design

Enrollment
30 (Actual)
Biospecimen Retention
Samples With DNA
Biospecimen Description
Genetic tests will be carried out in a subset of subject in order to confirm XLHED status.

8. Arms, Groups, and Interventions

Arm Title
XLHED affected Males
Arm Description
All males ages 4 and up affected by XLHED
Arm Title
Females affected by XLHED
Arm Description
Adult females (ages 18-45) affected by XLHED
Arm Title
Unaffected females
Arm Description
Unaffected adult female controls (ages 18-45)
Primary Outcome Measure Information:
Title
To collect demographic and clinical status information in XLHED-affected males, adult females at risk for XLHED and adult female controls
Description
To collect demographic and clinical status information in XLHED-affected males, adult females at risk for XLHED and adult female controls using a medical questionnaire
Time Frame
Study day 1
Title
To test and refine a computer algorithm for facial recognition of XLHED
Description
To test and refine a computer algorithm for facial recognition of XLHED based on 2D facial photographs obtained from subjects at risk for XLHED and controls
Time Frame
Study day 1
Title
To evaluate 3-dimensional facial imaging technology for mapping craniofacial development in XLHED males
Description
To evaluate 3-dimensional facial imaging technology for mapping craniofacial development in XLHED males
Time Frame
Study day 1
Title
To test for the presence of genetic mutations in subjects at risk for XLHED
Description
To test for the presence of genetic mutations in subjects at risk for XLHED who lack prior genetic diagnosis
Time Frame
Study day 1
Title
To test the validity of a using saliva samples for genetic testing
Description
To test the validity of a using saliva samples for genetic testing buy simultaneously perform genetic testing on blood and salvia and comparing the mutations identified
Time Frame
Study day 1

10. Eligibility

Sex
All
Minimum Age & Unit of Time
4 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Females of original gender of age 18-45 years who are registered and attending the 2013 NFED Family Conference. This will include those at risk for XLHED and controls XLHED-affected males of original gender of age 4 yrs and up who are registered and attending the 2013 NFED Family Conference Provide informed consent/assent Exclusion Criteria: Subjects who are not able or are not willing to comply with the procedures of this protocol Subjects with any major medical problem that will prevent them from participating in this study Male subjects who participated in the prior study ECP-003 sponsored by Edimer Pharmaceuticals Inc. in May 2011 in San Francisco, CA Males at risk for XLHED with prior genetic testing that did not reveal an EDA mutation
Study Population Description
XLHED affected males and females and unaffected female controls
Sampling Method
Non-Probability Sample
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dorothy K Grange, MD
Organizational Affiliation
Washington University School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Omni Houston Hotel
City
Houston
State/Province
Texas
ZIP/Postal Code
77056
Country
United States

12. IPD Sharing Statement

Links:
URL
http://edimerpharma.com
Description
Sponsor website

Learn more about this trial

Phenotypic Properties in Individuals Affected With XLHED

We'll reach out to this number within 24 hrs